The FDA Has Granted 510(k) Clearance To Surmodics' Pounce Low Profile Thrombectomy System For Non-surgical Removal Of Thrombi & Emboli From The Peripheral Arterial Vasculature In Vessels 2mm-4mm In Diameter, Sizes Typical Of Vessels Found Below The Knee
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted 510(k) clearance to Surmodics' Pounce Low Profile Thrombectomy System for non-surgical removal of thrombi and emboli from peripheral arterial vasculature in vessels 2mm-4mm in diameter, typically found below the knee.
June 14, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Surmodics receives FDA 510(k) clearance for its Pounce Low Profile Thrombectomy System, allowing non-surgical removal of thrombi and emboli from peripheral arterial vessels.
The FDA 510(k) clearance for Surmodics' Pounce Low Profile Thrombectomy System is a significant milestone for the company. This regulatory approval allows Surmodics to market and sell the product, which can lead to increased revenues and potentially boost the stock price in the short term. The news is highly relevant and important for investors in SRDX, as it directly impacts the company's product offerings and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100